vs
Side-by-side financial comparison of PROSPERITY BANCSHARES INC (PB) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $367.6M, roughly 1.9× PROSPERITY BANCSHARES INC). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs -104.7%, a 136.4% gap on every dollar of revenue. Over the past eight quarters, PROSPERITY BANCSHARES INC's revenue compounded faster (19.2% CAGR vs -2.9%).
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
PB vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $367.6M | $699.9M |
| Net Profit | $116.3M | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | — | -100.7% |
| Net Margin | 31.6% | -104.7% |
| Revenue YoY | — | -3.7% |
| Net Profit YoY | -10.7% | -3583.4% |
| EPS (diluted) | $1.16 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $367.6M | — | ||
| Q4 25 | $275.0M | — | ||
| Q3 25 | $273.4M | $699.9M | ||
| Q2 25 | $267.7M | $613.9M | ||
| Q1 25 | $265.4M | $692.8M | ||
| Q4 24 | $267.8M | $707.8M | ||
| Q3 24 | $261.7M | $727.1M | ||
| Q2 24 | $258.8M | $637.0M |
| Q1 26 | $116.3M | — | ||
| Q4 25 | $139.9M | — | ||
| Q3 25 | $137.6M | $-733.0M | ||
| Q2 25 | $135.2M | $-255.4M | ||
| Q1 25 | $130.2M | $-12.7M | ||
| Q4 24 | $130.1M | $-178.4M | ||
| Q3 24 | $127.3M | $-19.9M | ||
| Q2 24 | $111.6M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | 65.1% | — | ||
| Q3 25 | 64.4% | -100.7% | ||
| Q2 25 | 64.3% | -29.4% | ||
| Q1 25 | 62.7% | 4.7% | ||
| Q4 24 | 62.0% | -14.2% | ||
| Q3 24 | 62.1% | 2.1% | ||
| Q2 24 | 55.2% | -18.4% |
| Q1 26 | 31.6% | — | ||
| Q4 25 | 50.9% | — | ||
| Q3 25 | 50.3% | -104.7% | ||
| Q2 25 | 50.5% | -41.6% | ||
| Q1 25 | 49.1% | -1.8% | ||
| Q4 24 | 48.6% | -25.2% | ||
| Q3 24 | 48.6% | -2.7% | ||
| Q2 24 | 43.1% | -23.2% |
| Q1 26 | $1.16 | — | ||
| Q4 25 | $1.48 | — | ||
| Q3 25 | $1.45 | $-10.78 | ||
| Q2 25 | $1.42 | $-3.77 | ||
| Q1 25 | $1.37 | $-0.19 | ||
| Q4 24 | $1.36 | $-2.54 | ||
| Q3 24 | $1.34 | $-0.30 | ||
| Q2 24 | $1.17 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $98.1M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $8.2B | $2.0B |
| Total Assets | $43.6B | $5.7B |
| Debt / EquityLower = less leverage | — | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | $8.2B | — | ||
| Q4 25 | $7.6B | — | ||
| Q3 25 | $7.7B | $2.0B | ||
| Q2 25 | $7.6B | $2.8B | ||
| Q1 25 | $7.5B | $3.0B | ||
| Q4 24 | $7.4B | $3.0B | ||
| Q3 24 | $7.4B | $3.2B | ||
| Q2 24 | $7.3B | $3.2B |
| Q1 26 | $43.6B | — | ||
| Q4 25 | $38.5B | — | ||
| Q3 25 | $38.3B | $5.7B | ||
| Q2 25 | $38.4B | $6.4B | ||
| Q1 25 | $38.8B | $6.5B | ||
| Q4 24 | $39.6B | $6.4B | ||
| Q3 24 | $40.1B | $6.8B | ||
| Q2 24 | $39.8B | $6.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | — | 7.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $78.3M | — | ||
| Q3 25 | $194.8M | $-45.5M | ||
| Q2 25 | $98.2M | $-46.8M | ||
| Q1 25 | $178.2M | $65.6M | ||
| Q4 24 | $-205.8M | $63.7M | ||
| Q3 24 | $274.6M | $117.9M | ||
| Q2 24 | $216.5M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $68.5M | — | ||
| Q3 25 | $185.7M | $-94.7M | ||
| Q2 25 | $91.8M | $-84.3M | ||
| Q1 25 | $171.1M | $9.4M | ||
| Q4 24 | $-210.7M | $16.5M | ||
| Q3 24 | $270.2M | $71.4M | ||
| Q2 24 | $211.8M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 24.9% | — | ||
| Q3 25 | 67.9% | -13.5% | ||
| Q2 25 | 34.3% | -13.7% | ||
| Q1 25 | 64.5% | 1.4% | ||
| Q4 24 | -78.7% | 2.3% | ||
| Q3 24 | 103.3% | 9.8% | ||
| Q2 24 | 81.8% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.3% | 7.0% | ||
| Q2 25 | 2.4% | 6.1% | ||
| Q1 25 | 2.7% | 8.1% | ||
| Q4 24 | 1.8% | 6.7% | ||
| Q3 24 | 1.7% | 6.4% | ||
| Q2 24 | 1.8% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.56× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | -1.58× | — | ||
| Q3 24 | 2.16× | — | ||
| Q2 24 | 1.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
